JPH0449536B2 - - Google Patents

Info

Publication number
JPH0449536B2
JPH0449536B2 JP58209712A JP20971283A JPH0449536B2 JP H0449536 B2 JPH0449536 B2 JP H0449536B2 JP 58209712 A JP58209712 A JP 58209712A JP 20971283 A JP20971283 A JP 20971283A JP H0449536 B2 JPH0449536 B2 JP H0449536B2
Authority
JP
Japan
Prior art keywords
group
general formula
compound
reaction
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58209712A
Other languages
Japanese (ja)
Other versions
JPS60100542A (en
Inventor
Kinji Hashimoto
Kyoto Goto
Yoshiaki Tsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP58209712A priority Critical patent/JPS60100542A/en
Publication of JPS60100542A publication Critical patent/JPS60100542A/en
Publication of JPH0449536B2 publication Critical patent/JPH0449536B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳现な説明】 本発明は−テトラアルコキシナ
フタレン誘導䜓及びその塩に関する。 本発明の䞊蚘誘導䜓は、文献未茉の新芏化合物
であ぀お、䞋蚘䞀般匏(1)で衚わされる。 〔匏䞭R1は䜎玚アルコキシ基を瀺す。R2及び
R3は䞀方が氎酞基又は䜎玚アルカノむルオキシ
基を瀺し、他方が基【匏】を瀺す。該基にお いおR4及びR5は同䞀又は盞異な぀お氎玠原子、
䜎玚アルキル基、シクロアルキル基、プニル環
䞊に眮換基ずしお䜎玚アルコキシ基を有するこず
のあるプニル基又はプニル環䞊に眮換基ずし
お䜎玚アルコキシ基を有するこずのあるプニル
䜎玚アルキル基を瀺す。たたR4及びR5は酞玠原
子もしくは窒玠原子を介しもしくは介するこずな
く互に結合しお、隣接する窒玠原子ず共に耇玠環
基を圢成しおもよく、該耇玠環基は曎にプニル
䜎玚アルキル基を眮換基ずしお有しおいおもよ
い。〕 䞊蚘䞀般匏(1)䞭、R1で定矩される䜎玚アルコ
キシ基ずしおは、䟋えばメトキシ、゚トキシ、プ
ロポキシ、む゜プロポキシ、ブトキシ、む゜ブト
キシ、sec−ブトキシ、tert−ブトキシ基等を䟋
瀺できる。 R2及びR3で定矩される䜎玚アルカノむルオキ
シ基ずしおは、䟋えばアセトキシ、プロピオニル
オキシ、ブチリルオキシ、む゜ブチリルオキシ、
バレリルオキシ、む゜バレリルオキシ基等を䟋瀺
できる。 たた基【匏】を圢成するR4及びR5で瀺さ れる䜎玚アルキル基ずしおは、䟋えばメチル、゚
チル、プロピル、む゜プロピル、ブチル、む゜ブ
チル、sec−ブチル、tert−ブチル基等を、シク
ロアルキル基ずしおは、シクロプロピル、シクロ
ブチル、シクロペンチル、シクロヘキシル、シク
ロヘプチル及びシクロオクチル基を、プニル環
䞊に眮換基ずしお䜎玚アルコキシ基を有するこず
のあるプニル基ずしおは、䟋えばプニル、
−メトキシプニル、−メトキシプニル、
−ブトキシプニル、−メトキシ−−゚トキ
シプニル、−ゞメトキシプニル、
−ゞプロポキシプニル、−トリメ
トキシプニル、−トリ゚トキシプ
ニル基等を、曎にプニル環䞊に眮換基ずしお䜎
玚アルコキシ基を有するこずのあるプニル䜎玚
アルキル基ずしおは、䟋えばベンゞル、α−プ
ネチル、β−プネチル、−プニルプロピ
ル、−プニルプロピル、−プニルプロピ
ル、−プニルブチル、−プニルブチル、
−プニルブチル、−プニルブチル、−
プニルペンチル、−プニルペンチル、−
プニルペンチル、−プニルヘキシル、−
プニルヘキシル、−プニルヘキシル、
−ゞメチル−−プニル゚チル基等の非眮換
のプニルアルキル基及び䟋えば−メトキシベ
ンゞル、−゚トキシ−β−プネチル、−プ
ロポキシ−β−プネチル、−−ゞメ
トキシプニルプロピル、−−ゞ゚
トキシプニルブチル、−トリメト
キシベンゞル、−ゞメトキシ−β−プネ
チル、−−ゞメトキシプニルヘキ
シル基等の眮換プニルアルキル基を倫々䟋瀺す
るこずができる。 曎に䞊蚘基【匏】が圢成し埗る耇玠環基ず しおは、䟋えば−ピロリゞニル、ピペリゞノ、
ピペラゞニル、モルホリノ基等を䟋瀺でき、プ
ニル䜎玚アルキル眮換の䞊蚘耇玠環基ずしおは、
䞊蚘非眮換のプニルアルキル基で眮換されたピ
ペラゞニル基䟋えば−ベンゞルピペラゞニル、
−α−プネチルピペラゞニル、−β−プ
ネチルピペラゞニル基等を䟋瀺するこずができ
る。 䞊蚘䞀般匏(1)で衚わされる本発明誘導䜓及びそ
の塩即ち無機もしくは有機酞の付加塩は、いずれ
も心臓疟患及び本胜性高血圧等の高血圧症の治療
及び予防効果を有しおおり、之等の薬理䜜甚を利
甚した医薬品ずしお、䟋えばう぀血性心䞍党、狭
心症、心筋梗塞、高血圧、心臓䞍敎脈、運動亢進
性心臓症候矀等の治療及び予防薬ずしお有甚であ
る。 本発明誘導䜓は、皮々の方法により補造され
る。その奜たしい具䜓䟋を䞋蚘反応工皋匏に瀺し
詳述する。 〔匏䞭R1、R4及びR5は前蚘に同り。R2′及び
R3′は䞀方が氎酞基で他方が基【匏】R4及 びR5は前蚘に同じを瀺す。たたR2″及びR3″は
䞀方が䜎玚アルカノむルオキシ基で他方が基
【匏】R4及びR5は前蚘に同じを瀺す。〕 反応行皋匏−によれば、䞀般匏(2)で衚わされ
る公知のアルデヒドを゚ポキシ䜓に倉換させお埗
られる䞀般匏(3)の゚ポキシドに、䞀般匏(4)のアミ
ンを反応させるこずにより䞀般匏(1)äž­R2及びR3
の䞀方が氎酞基である本発明化合物1aを収
埗でき、該化合物1aをアシル化反応させる
こずにより䞀般匏(1)äž­R2及びR3の䞀方が䜎玚ア
ルカノむルオキシ基である本発明化合物1b
を収埗できる。 䞊蚘における䞀般匏(2)のアルデヒドの゚ポキシ
化反応は、公知の方法、䟋えばメルクルG.
Mašrklらの方法〔Angew.Chem.85867
1973〕に準じお実斜するこずができる。即ち玄
〜モルの盞関移動觊媒、䟋えばベンゞルト
リ゚チルアンモニりムクロラむド、テトラ−−
ブチルアンモニりムペヌダむド等の玚アンモニ
りム塩の存圚䞋、50氎酞化アルカリずゞクロル
メタンずの二盞系で、䞀般匏(2)のアルデヒドず、
これに察し玄〜1.3倍モル量のトリメチルスル
ホニりムペヌダむドずを反応させるこずにより行
なわれる。該反応は玄50℃前埌の枩床条件䞋に、
通垞24〜48時間で完結し、これにより䞀般匏(3)の
゚ポキシドを埗る。該゚ポキシド(3)は文献未茉の
新芏化合物であり、本発明の−テ
トラアルコキシナフタレン誘導䜓の合成䞭間䜓ず
しお重芁なものである。 䞊蚘゚ポキシド(3)ず䞀般匏(4)で衚わされる公知
のアミンずの反応は、通垞適圓な溶媒䞭で行なわ
れる。溶媒ずしおは反応に悪圱響を䞎えない各皮
のものを䜿甚でき、特にメタノヌル、゚タノヌ
ル、む゜プロパノヌル、tert−ブタノヌル、む゜
アミルアルコヌル等のアルコヌル系溶媒が奜適で
ある。゚ポキシド(3)に察するアミン(4)の䜿甚割合
は特に限定されないが、通垞少なくずも圓量、䞀
般には玄〜20倍圓量の範囲ずされる。反応は玄
25℃〜溶媒の沞点範囲の枩床条件䞋に、通垞玄
時間〜10日間で行なわれる。この反応により䞀般
匏1aで衚わされる本発明化合物を埗る。こ
れは通垞䞀般匏1a䞭、R2′が氎酞基である化
合物ず、R3′が氎酞基である化合物ずの混合物で
あり、䞀般には原料ずする䞀般匏(3)の゚ポキシド
がナフタレン環に電子䟛䞎基であるアルコキシ基
R1を有しおいるため、R3′が氎酞基である化
合物が䞻成積䜓ずしお埗られる堎合が倚い。之等
の混合物は垞法に埓い分離するこずができる。 䞊蚘反応に匕き続く䞀般匏1aの化合物の
アシル化反応は、通垞の方法に埓い、塩基䟋えば
ピリゞン、トリ゚チルアミン等の存圚䞋に、アシ
ル化剀䟋えば䜎玚アルキルカルボン酞の無氎物も
しくは酞ハラむドを甚いお行なわれる。䞀般匏
1aの化合物に察する塩基及びアシル化剀の䜿
甚割合は、適宜に遞択できるが、通垞塩基を玄
〜100倍圓量及びアシル化剀を玄〜10倍圓量の
範囲で甚いるのがよい。反応は玄〜30℃の枩床
条件䞋に、玄〜20時間を芁しお行なわれ、これ
により䞀般匏1bで衚わされる本発明化合物
を収埗できる。 䞊蚘各行皋で埗られる目的物は、慣甚の分離手
段、䟋えば溶媒抜出、再結晶、カラムクロマトグ
ラフむヌ等により容易に単離粟補するこずができ
る。 〔匏䞭R1、R4及びR5は前蚘に同じ。〕 䞊蚘反応行皋匏−によれば、䞀般匏(2)のアル
デヒドをアルカリ金属シアン化物ず反応させお、
䞀般匏(5)のシアンヒドリン化合物ずした埌、これ
を還元、アルキル化反応させるこずにより、䞀般
匏(1)äž­R2が氎酞基である本発明化合物を収埗で
きる。 䞀般匏(2)のアルデヒドずアルカリ金属シアン化
物ずの反応は、通垞の方法、䟋えば亜硫酞氎玠ナ
トリりム塩を経る方法に埓い実斜できる〔W.
Revue et al.J.Am.Chem.Soc.791932
1957〕。即ち䞀般匏(2)のアルデヒドを、゚ヌテ
ル、テトラヒドロフラン、ゞオキサン等に懞濁又
は溶解させ、氷冷䞋にお該アルデヒドに察しお
〜倍モル皋床の亜硫酞氎玠ナトリりム氎溶液を
加え、30分〜時間撹拌を続ける。その埌析出し
た結晶を取する。曎に埗られる結晶を氎に懞濁
させ、〜倍モル皋床のアルカリ金属シアン化
物の氎溶液を加える。撹拌を〜時間続けた
埌、析出した結晶を取し、也燥する。かくしお
䞀般匏(5)のシアンヒドリン化合物を埗る。これは
文献未茉の新芏化合物であり、本発明の
−テトラアルコキシナフタレン誘導䜓の合
成䞭間䜓ずしお重芁なものである。 䞊蚘シアンヒドリン化合物(5)の還元反応は、通
垞の方法に埓い、適圓な還元剀、䟋えばLiAlH4
をやパラゞりム−炭玠系觊媒等甚いた接觊氎添や
酢酞、トリフルオロ酢酞等の有機酞を加えお
NaBH4等を甚いた方法等により行なうこずがで
きる。特に詊薬の甚い易さ、倧量合成の可胜性を
考慮すればトリフルオロ酢酞−NaBH4系を甚い
る方法〔N.Umino et al.Tetrahedron Lett.
3328751977〕が奜たしい。該方法はより詳现
には、゚ヌテル、テトラヒドロフラン、ゞオキサ
ン等の溶媒、奜たしくはテトラヒドロフラン䞭
に、シアンヒドリン化合物(5)に察しお玄〜倍
モル、奜たしくは玄倍モル量のNaBH4を懞濁
させ、これに氷冷䞋にシアンヒドリン化合物(5)に
察しお玄倍モル量のトリフルオロ酢酞を加え、
次いで䞊蚘混液䞭にシアンヒドリン化合物(5)のテ
トラヒドロフラン溶液を加え、玄〜50℃、奜た
しくは〜20℃皋床の枩床䞋に通垞玄〜10時間
を芁しお実斜される。かくしお䞀般匏1cの化
合物を埗る。 䞊蚘還元反応により埗られる䞀般匏1cの化
合物のアルキル化反応は、通垞の方法、䟋えば適
圓な溶媒䞭で脱酞剀及びアルキル化剀を甚いお行
なわれる。脱酞剀ずしおは䞀般に甚いられる各皮
のもの、䟋えばトリ゚チルアミン、ピリゞン等の
有機アミン類や炭酞カリりム、炭酞ナトリりム等
を利甚できる。アルキル化剀ずしおは通垞のハロ
ゲン化アルキル、䟋えばペり化メチル、゚チルブ
ロマむド、ベンゞルクロラむド、プネチルブロ
マむド、シクロヘキシルクロラむド等を利甚でき
る。たた溶媒ずしおは−ゞメチルホルムア
ミド、ゞメチルスルホキシド、リン酞ヘキサメチ
ルトリアミド、テトラヒドロフラン、アセトン等
の極性溶媒を奜適に甚いるこずができる。脱酞剀
及びアルキル化剀の䜿甚量は、特に制限はない
が、通垞䞀般匏1cの化合物に察しお、脱酞剀
は等モル〜倍モル皋床、ハロゲン化アルキルは
等モル〜倍モル皋床の範囲ずされるのがよい。
反応は䞀般に宀枩付近で進行し、玄〜48時間で
完結する。たた䞊蚘アルキル化反応は、還元的ア
ルキル化ず呌ばれる通垞の方法によ぀おも実斜す
るこずができる。この方法は䞀般匏1cの化合
物アミンず任意のケトン又はアルデヒドずの
シツフ塩基を還元するこずにより行なわれる。ケ
トン及びアルデヒドずしおは、䟋えばアセトン、
シクロヘキサノン、アセトプノン、ベンズアル
デヒド、−ブタノン、アニスアルデヒド等を䟋
瀺できる。之等は通垞䞀般匏1cのアミンに察
しお等モル〜10倍モル、奜たしくは玄倍モル前
埌の量で甚いられる。反応はメタノヌル、゚タノ
ヌル、ゞメチルホルムアミド−゚タノヌル、ゞメ
チルホルムアミド−メタノヌル混合溶媒等の適圓
な溶媒䞭に䞀般匏1cのアミン及びケトン又は
アルデヒドを加え、この混合物䞭に氷冷䞋に還元
剀䟋えばNaBH4、NaBH3CN等の等モル〜倍
モル量、奜たしくは等モル〜倍モル量䞀般匏
1cの化合物に察するを加えるこずにより玄
30分〜20時間皋床で終了する。たた䞊蚘方法は、
他にパラゞりム−炭玠系觊媒を甚いる接觊氎添に
よ぀おも行ない埗る。この堎合、䞊蚘溶媒に溶解
した䞀般匏1cの化合物ずケトン又はアルデヒ
ドずの混合物に、垞圧〜気圧の圧力䞋、宀枩〜
50℃皋床の枩床条件䞋に氎玠添加を行なうのが奜
たしい。かくしお䞀般匏1dの本発明化合物
を埗る。 たた䞀般匏(1)äž­R2が䜎玚アルカノむルオキシ
基である本発明化合物は、䞊蚘反応行皋匏−に
瀺す方法により埗られる䞀般匏1dの化合物
に、前蚘反応行皋匏−に瀺す䞀般匏1aの
化合物のアシル化反応ず同様の反応を適甚するこ
ずによ぀おも補造するこずができる。 䞊蚘各反応行皋により埗られる化合物は、慣甚
の分離手段、䟋えば溶媒抜出、再結晶、カラムク
ロマトグラフむヌ等により容易に単離粟補するこ
ずができる。 本発明の前蚘䞀般匏(1)で衚わされる化合物は、
これに適圓な無機もしくは有機酞を反応させるこ
ずにより、薬理的に蚱容される酞付加塩ずするこ
ずができ、本発明はかかる塩をも包含する。䞊蚘
塩の圢成反応は垞法に埓うこずができ、その際甚
いられる酞も通垞のものでよい。その具䜓䟋ずし
おは䟋えば硫酞、塩酞、硝酞等の無機酞及びシナ
り酞、マレむン酞、フマル酞、ク゚ン酞等の有機
酞を䟋瀺できる。曎に本発明化合物には光孊異性
䜓が考えられ、本発明はかかる異性䜓をも圓然に
包含する。 以䞋、本発明化合物の補造に利甚する䞀般匏(3)
の゚ポキシド及び䞀般匏(5)のシアンヒドリン化合
物の補造䟋を参考䟋ずしお挙げ、次いで本発明化
合物の補造䟋を挙げる。 参考䟋  −−゚ポキシ゚チル−
−テトラメトキシナフタレン〔䞀般匏(3)、
R1OCH3〕の補造 −テトラメトキシ−−ナフタ
レンカルボアルデヒド5.620mM、トリメチ
ルスルホニりムペヌダむド4.321mM及び
テトラ−−ブチルアンモニりムペヌダむド140
mgを、塩化メチレン100ml及び50氎酞化ナトリ
りム溶液80mlに溶解し、撹拌䞋に50℃で24時間加
熱し、反応させる。反応終了埌、有機局を分取
し、也燥濃瞮しお淡黄色結晶5.6を埗る。この
ものぱヌテル−ヘキサン混合溶媒から再結
晶するこずができる。 融点 84〜85℃再結晶埌 1H−NMRCDCl3、TMS、ppm Ύ6.832H、6.622H、3.94
3H、3.913H、3.883H、3.82
3H、4.43dd4.42.61H、3.22dd5.7
4.41H、2.78dd5.72.61H 参考䟋  α−ヒドロキシ−−テトラメト
キシナフタレン−−アセトニトリル〔䞀般匏
(5)、R1OCH3〕の補造 −テトラメトキシ−−ナフタ
レンカルボアルデヒド2.4のテトラヒドロフラ
ン10ml溶液に、亜硫酞氎玠ナトリりム2.1の氎
ml溶液を宀枩で加え、30分撹拌する。反応溶液
に氷冷䞋゚チル゚ヌテル60mlを加え、析出した結
晶を取し、む゜プロパノヌルで掗浄する。埗ら
れる結晶を氎30mlに懞濁し、シアン化ナトリりム
の氎ml溶液を加え、30分間撹拌埌、生成す
る結晶を取しお目的物を埗る。 融点 110〜116℃ 1H−NMRCDCl3、TMS、ppm Ύ6.873H、5.877.31H、4.12
7.31H、3.943H、3.89
6H、3.853H 実斜䟋  トリフルオロ酢酞3.1のテトラヒドロフラン
ml溶液を、氎玠化ホり玠ナトリりムのテト
ラヒドロフラン20ml溶液䞭に、20℃以䞋で加え
る。この混合物䞭に、参考䟋で埗たα−ヒドロ
キシ−−テトラメトキシナフタレ
ン−−アセトニトリル1.655.4mMのテト
ラヒドロフラン10ml溶液を20℃以䞋で加え、その
埌宀枩で時間撹拌を続ける。反応混合物を氎に
移し、塩化メチレンで抜出し、有機局を也燥、濃
瞮埌、シリカゲルカラムクロマトグラフむヌメ
タノヌルクロロホルムで粟補しお、α−アミ
ノメチル−−テトラメトキシナフ
タレン−−メタノヌルの500mgを油状物ずしお
埗る。 埗られた化合物の構造及び物性を第衚に瀺
す。 実斜䟋  α−アミノメチル−−テトラメ
トキシナフタレン−−メタノヌル310mg
1mM及びアセトン300mgのメタノヌルml溶
液に氷冷䞋NaBH3CN65mgをゆ぀くり加える。
その埌、宀枩に埐々にもどし16時間撹拌を続け
る。反応液を氎に移し、クロロホルムで抜出し、
有機局を也燥埌、濃瞮しお埗られる粗生成物をシ
リカゲルクロマトグラフむヌクロロホルムメ
タノヌル201Vで粟補しおα−−メ
チル゚チルアミノメチル−−テ
トラメトキシナフタレン−−メタノヌル272mg
収率78を埗る。化合物の構造及び物性を第
衚に瀺す。 実斜䟋 〜 䞊蚘実斜䟋及びず同様にしお、第衚に瀺
す実斜䟋〜の各化合物を埗た。たた之等各化
合物は、埌述する実斜䟋13に蚘茉の方法に埓぀お
も補造される。 実斜䟋 10 α−ピペリゞノメチル−−テト
ラメトキシナフタレン−−メタノヌル750mgを
ピリゞンmlに溶解し、無氎酢酞mlを加え、25
℃で時間撹拌する。氎に移し酢酞゚チルで抜出
し有機局を氎掗する。有機局を濃瞮埌、埗られた
粗生成物をシリカゲルクロマトグラフむヌメタ
ノヌルクロロホルム1/30で粟補するず
740mg88の−−アセトキシ−−ピペ
リゞノ゚チル−−テトラメトキ
シナフタレンを油状物質ずしお埗る。その構造及
び物性を第衚に瀺す。 実斜䟋 11及び12 䞊蚘実斜䟋10ず同様にしお䞋蚘第衚に瀺す実
斜䟋11及び12の化合物を埗た。 【衚】 【衚】 【衚】 実斜䟋 13 参考䟋で埗た−−゚ポキシ゚チル
−−テトラメトキシナフタレン
ず、む゜プロピルアミンずをメタノヌル60
mlに溶解し、日間宀枩で撹拌する。その埌メタ
ノヌルを留去し、埗られた油状物質をシリカゲル
カラムクロマトグラフむヌクロロホルムメタ
ノヌル30/1で粟補しお360mg収率
のβ−−メチル゚チルアミノ−
−テトラメトキシナフタレン−−゚タノ
ヌルを油状物質ずしお埗る。このものは、゚タノ
ヌルに溶解埌、也燥し、塩酞で酞性ずし、゚ヌテ
ルを加えるこずにより結晶ずしお取するこずが
でき、その物性は前蚘実斜䟋で埗た化合物のそ
れず䞀臎した。 たた䞊蚘シリカゲルカラムクロマトグラフむヌ
においお、さらにクロロホルムメタノヌル2
比で展開を続けるこずにより、400
mg収率33のα−−メチル゚チルアミ
ノメチル−−テトラメトキシナフ
タレン−−メタノヌルを油状物質ずしお埗る。
この油状物質は、゚タノヌルに溶解し、也燥し、
塩酞で酞性ずした埌に、゚ヌテルを加えお結晶ず
しお取するこずができる。この化合物の構造及
び物性を実斜䟋No.13ずしお第衚に瀺す。 実斜䟋 14〜21 実斜䟋13ず同様にしお、前蚘実斜䟋〜に瀺
す各化合物ず共に、埌蚘第衚に瀺す実斜䟋14〜
21の各化合物を埗た。 実斜䟋 22〜24 前蚘実斜䟋10ず同様の操䜜を行な぀お、䞋蚘第
衚に瀺す実斜䟋22〜24の各化合物を埗た。 【衚】 【衚】
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to 1,4,5,8-tetraalkoxynaphthalene derivatives and salts thereof. The above-mentioned derivative of the present invention is a novel compound that has not been described in any literature, and is represented by the following general formula (1). [In the formula, R 1 represents a lower alkoxy group. R 2 and
One of R 3 represents a hydroxyl group or a lower alkanoyloxy group, and the other represents a group [Formula]. In this group, R 4 and R 5 are the same or different and are hydrogen atoms,
A lower alkyl group, a cycloalkyl group, a phenyl group that may have a lower alkoxy group as a substituent on the phenyl ring, or a phenyl lower alkyl group that may have a lower alkoxy group as a substituent on the phenyl ring. Furthermore, R 4 and R 5 may be bonded to each other with or without an oxygen atom or a nitrogen atom to form a heterocyclic group together with the adjacent nitrogen atom, and the heterocyclic group may further include a phenyl lower alkyl group. It may be included as a substituent. ] In the above general formula (1), examples of the lower alkoxy group defined by R 1 include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy groups. Examples of lower alkanoyloxy groups defined for R 2 and R 3 include acetoxy, propionyloxy, butyryloxy, isobutyryloxy,
Examples include valeryloxy and isovaleryloxy groups. Examples of lower alkyl groups represented by R 4 and R 5 forming the group [formula] include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl groups, etc. represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups, and phenyl groups which may have a lower alkoxy group as a substituent on the phenyl ring include, for example, phenyl, 1
-methoxyphenyl, 2-methoxyphenyl, 3
-butoxyphenyl, 2-methoxy-3-ethoxyphenyl, 3,4-dimethoxyphenyl, 2,
4-dipropoxyphenyl, 3,4,5-trimethoxyphenyl, 2,4,6-triethoxyphenyl groups, etc., and phenyl lower which may further have a lower alkoxy group as a substituent on the phenyl ring. Examples of the alkyl group include benzyl, α-phenethyl, β-phenethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-phenylbutyl, 2-phenylbutyl,
3-phenylbutyl, 4-phenylbutyl, 1-
Phenylpentyl, 3-phenylpentyl, 5-
Phenylpentyl, 1-phenylhexyl, 3-
Phenylhexyl, 5-phenylhexyl, 1,
Unsubstituted phenylalkyl groups such as 1-dimethyl-2-phenylethyl and e.g. 2-methoxybenzyl, 3-ethoxy-β-phenethyl, 4-propoxy-β-phenethyl, 1-(2,3-dimethoxyphenyl) ) propyl, 1-(3,4-diethoxyphenyl)butyl, 3,4,5-trimethoxybenzyl, 3,4-dimethoxy-β-phenethyl, 4-(2,3-dimethoxyphenyl)hexyl group Examples of substituted phenylalkyl groups include the following. Furthermore, examples of the heterocyclic group that can be formed by the above group [formula] include 1-pyrrolidinyl, piperidino,
Examples include piperazinyl and morpholino groups, and the above-mentioned heterocyclic groups substituted with phenyl lower alkyl include:
A piperazinyl group substituted with the above unsubstituted phenylalkyl group, for example, N-benzylpiperazinyl,
Examples include N-α-phenethylpiperazinyl and N-β-phenethylpiperazinyl groups. The derivatives of the present invention represented by the above general formula (1) and their salts, that is, addition salts of inorganic or organic acids, all have therapeutic and preventive effects on heart diseases and hypertension such as instinctive hypertension, etc. It is useful as a drug that utilizes the pharmacological action of, for example, as a therapeutic or preventive agent for congestive heart failure, angina pectoris, myocardial infarction, hypertension, cardiac arrhythmia, hyperkinetic heart syndrome, etc. The derivatives of the present invention can be produced by various methods. Preferred specific examples thereof are shown in the following reaction scheme and will be described in detail. [In the formula, R 1 , R 4 and R 5 are the same as above. R 2 ′ and
One of R 3 ' is a hydroxyl group and the other is a group (R 4 and R 5 are the same as above). Further, R 2 ″ and R 3 ″ represent a lower alkanoyloxy group on one side and a group on the other hand (R 4 and R 5 are the same as above). ] According to Reaction Scheme-1, the amine of the general formula (4) is reacted with the epoxide of the general formula (3) obtained by converting a known aldehyde represented by the general formula (2) into an epoxy form. According to general formula (1), R 2 and R 3
The compound of the present invention (1a) in which one of R 2 and R 3 in the general formula (1) is a lower alkanoyloxy group can be obtained by subjecting the compound (1a) to an acylation reaction. Compound (1b)
can be obtained. The epoxidation reaction of the aldehyde of general formula (2) in the above can be carried out by a known method, such as Merkl (G.
[Angew.Chem., 85 , 867]
(1973)]. That is, about 1 to 5 mole % of a phase transfer catalyst, such as benzyltriethylammonium chloride, tetra-n-
In the presence of a quaternary ammonium salt such as butylammonium iodide, in a two-phase system of 50% alkali hydroxide and dichloromethane, aldehyde of general formula (2),
This is carried out by reacting with trimethylsulfonium iodide in an amount of about 1 to 1.3 times the molar amount. The reaction is carried out at a temperature of about 50°C.
The process is usually completed within 24 to 48 hours, thereby obtaining the epoxide of general formula (3). The epoxide (3) is a new compound that has not been described in any literature, and is important as a synthetic intermediate for the 1,4,5,8-tetraalkoxynaphthalene derivative of the present invention. The reaction between the epoxide (3) and the known amine represented by the general formula (4) is usually carried out in a suitable solvent. Various solvents can be used that do not adversely affect the reaction, and alcoholic solvents such as methanol, ethanol, isopropanol, tert-butanol, and isoamyl alcohol are particularly suitable. The ratio of amine (4) to epoxide (3) is not particularly limited, but is usually at least an equivalent, generally about 1 to 20 times the equivalent. The reaction is approx.
Under temperature conditions ranging from 25°C to the boiling point of the solvent, usually about 5
It will be done in hours to 10 days. This reaction yields the compound of the present invention represented by general formula (1a). This is usually a mixture of a compound in which R 2 ′ is a hydroxyl group in general formula (1a) and a compound in which R 3 ′ is a hydroxyl group, and generally, the epoxide of general formula (3) used as a raw material is formed into a naphthalene ring. Since it has an alkoxy group (R 1 ) which is an electron-donating group, compounds in which R 3 ' is a hydroxyl group are often obtained as the main product. Such mixtures can be separated according to conventional methods. The acylation reaction of the compound of general formula (1a) subsequent to the above reaction is performed using an acylating agent such as a lower alkyl carboxylic acid anhydride or acid halide in the presence of a base such as pyridine, triethylamine, etc., in accordance with a conventional method. It is done. The ratio of the base and acylating agent to the compound of general formula (1a) can be selected as appropriate, but usually the base is
-100 times equivalent and the acylating agent is preferably used in a range of about 1 to 10 times equivalent. The reaction is carried out at a temperature of about 0 to 30° C. for about 1 to 20 hours, whereby the compound of the present invention represented by general formula (1b) can be obtained. The target products obtained in each of the above steps can be easily isolated and purified by conventional separation means such as solvent extraction, recrystallization, column chromatography, etc. [In the formula, R 1 , R 4 and R 5 are the same as above. ] According to the reaction scheme-2 above, the aldehyde of general formula (2) is reacted with an alkali metal cyanide,
The compound of the present invention in which R 2 in the general formula (1) is a hydroxyl group can be obtained by converting the cyanohydrin compound of the general formula (5) into a cyanohydrin compound and then subjecting it to a reduction and alkylation reaction. The reaction between the aldehyde of general formula (2) and the alkali metal cyanide can be carried out according to a conventional method, for example, a method involving sodium bisulfite [W.
Revue et al., J.Am.Chem.Soc., 79 , 1932
(1957)]. That is, the aldehyde of general formula (2) is suspended or dissolved in ether, tetrahydrofuran, dioxane, etc., and 2
Add about 3 times the mole of sodium bisulfite aqueous solution and continue stirring for 30 minutes to 2 hours. Then, collect the precipitated crystals. Further, the obtained crystals are suspended in water, and an aqueous solution of alkali metal cyanide in an amount of about 2 to 3 times the mole is added. After stirring for 1 to 2 hours, the precipitated crystals are collected and dried. In this way, a cyanohydrin compound of general formula (5) is obtained. This is a new compound that has not been described in any literature, and 1, 4, and 1 of the present invention.
It is important as a synthetic intermediate for 5,8-tetraalkoxynaphthalene derivatives. The reduction reaction of the above cyanohydrin compound (5) is carried out using a suitable reducing agent such as LiAlH 4 according to a conventional method.
By catalytic hydrogenation using a palladium-carbon catalyst or by adding an organic acid such as acetic acid or trifluoroacetic acid,
This can be carried out by a method using NaBH 4 or the like. In particular, considering the ease of use of reagents and the possibility of mass synthesis, there is a method using trifluoroacetic acid-NaBH 4 system [N. Umino et al., Tetrahedron Lett.,
33, 2875 (1977)] is preferred. More specifically, the method involves suspending NaBH 4 in a molar amount of about 4 to 8 times, preferably about 5 times, relative to the cyanohydrin compound (5) in a solvent such as ether, tetrahydrofuran, dioxane, etc., preferably tetrahydrofuran. To this, add about 5 times the molar amount of trifluoroacetic acid to the cyanohydrin compound (5) under ice-cooling.
Next, a solution of the cyanohydrin compound (5) in tetrahydrofuran is added to the above mixed liquid, and the reaction is carried out at a temperature of about 0 to 50°C, preferably about 0 to 20°C, usually taking about 2 to 10 hours. Thus, a compound of general formula (1c) is obtained. The alkylation reaction of the compound of general formula (1c) obtained by the above reduction reaction is carried out by a conventional method, for example, using a deoxidizing agent and an alkylating agent in a suitable solvent. Various commonly used deoxidizing agents can be used, such as organic amines such as triethylamine and pyridine, potassium carbonate, and sodium carbonate. As the alkylating agent, common alkyl halides such as methyl iodide, ethyl bromide, benzyl chloride, phenethyl bromide, cyclohexyl chloride, etc. can be used. As the solvent, polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, hexamethyltriamide phosphate, tetrahydrofuran, and acetone can be suitably used. The amount of the deoxidizing agent and alkylating agent to be used is not particularly limited, but the amount of the deoxidizing agent is usually about 1 to 5 times the mole of the compound of general formula (1c), and the amount of the alkyl halide is about 1 to 6 times the mole of the compound of general formula (1c). It is preferable to set it in a range of about twice the molar amount.
The reaction generally proceeds around room temperature and is complete in about 5 to 48 hours. Further, the above alkylation reaction can also be carried out by a conventional method called reductive alkylation. This method is carried out by reducing the Schiff base of the compound of general formula (1c) (amine) and any ketone or aldehyde. Ketones and aldehydes include, for example, acetone,
Examples include cyclohexanone, acetophenone, benzaldehyde, 2-butanone, and anisaldehyde. These are usually used in an amount of equimolar to 10 times the amine of general formula (1c), preferably about 5 times the molar amount. The reaction is carried out by adding the amine of general formula (1c) and a ketone or aldehyde to a suitable solvent such as methanol, ethanol, dimethylformamide-ethanol, dimethylformamide-methanol mixed solvent, etc., and adding a reducing agent such as NaBH to this mixture under ice cooling. 4 , NaBH 3 CN, etc. in an equimolar to 5-fold molar amount, preferably in an equimolar to 2-fold molar amount (relative to the compound of general formula (1c)).
It takes about 30 minutes to 20 hours to complete. In addition, the above method
Alternatively, catalytic hydrogenation using a palladium-carbon catalyst may also be used. In this case, a mixture of the compound of general formula (1c) and a ketone or aldehyde dissolved in the above-mentioned solvent is added at room temperature to
It is preferable to perform hydrogenation at a temperature of about 50°C. In this way, the compound of the present invention of general formula (1d) is obtained. Further, the compound of the present invention in which R 2 in the general formula (1) is a lower alkanoyloxy group can be added to the compound of the general formula (1d) obtained by the method shown in the above reaction scheme-2, as shown in the above reaction scheme-1. It can also be produced by applying a reaction similar to the acylation reaction of the compound of general formula (1a). The compounds obtained by each of the above reaction steps can be easily isolated and purified by conventional separation means such as solvent extraction, recrystallization, column chromatography, etc. The compound represented by the general formula (1) of the present invention is:
By reacting this with a suitable inorganic or organic acid, a pharmacologically acceptable acid addition salt can be obtained, and the present invention also includes such a salt. The above-mentioned salt formation reaction can be carried out in accordance with a conventional method, and the acid used at that time may also be a conventional one. Specific examples include inorganic acids such as sulfuric acid, hydrochloric acid, and nitric acid, and organic acids such as oxalic acid, maleic acid, fumaric acid, and citric acid. Further, the compounds of the present invention may have optical isomers, and the present invention naturally includes such isomers. Below, general formula (3) used for the production of the compound of the present invention
Examples of the production of the epoxide and the cyanohydrin compound of general formula (5) will be listed as reference examples, and then production examples of the compounds of the present invention will be listed. Reference example 1 2-(1,2-epoxyethyl)-1,4,5,
8-tetramethoxynaphthalene [general formula (3),
1,4,5,8 -tetramethoxy-2-naphthalenecarbaldehyde 5.6g ( 20mM ), trimethylsulfonium iodide 4.3g (21mM) and tetra-n-butylammonium iodide 140
mg is dissolved in 100 ml of methylene chloride and 80 ml of 50% sodium hydroxide solution and heated under stirring at 50° C. for 24 hours to react. After the reaction is completed, the organic layer is separated, dried and concentrated to obtain 5.6 g of pale yellow crystals. This product can be recrystallized from a mixed solvent of ether/n-hexane. Melting point 84-85℃ (after recrystallization) 1 H-NMR (CDCl 3 , TMS, ppm) ή = 6.83 (s, 2H), 6.62 (s, 2H), 3.94 (s,
3H), 3.91 (s, 3H), 3.88 (s, 3H), 3.82 (s,
3H), 4.43 (dd, 4.4, 2.6, 1H), 3.22 (dd, 5.7,
4.4, 1H), 2.78 (dd, 5.7, 2.6, 1H) Reference example 2 α-hydroxy-1,4,5,8-tetramethoxynaphthalene-2-acetonitrile [general formula
(5), R 1 = OCH 3 ] To a solution of 2.4 g of 1,4,5,8-tetramethoxy-2-naphthalenecarbaldehyde in 10 ml of tetrahydrofuran, a solution of 2.1 g of sodium bisulfite in 6 ml of water was added at room temperature. Stir for 30 minutes. Add 60 ml of ethyl ether to the reaction solution under ice cooling, collect the precipitated crystals, and wash with isopropanol. The resulting crystals are suspended in 30 ml of water, a solution of 1 g of sodium cyanide in 4 ml of water is added, and after stirring for 30 minutes, the resulting crystals are collected to obtain 2 g of the desired product. Melting point 110-116℃ 1 H-NMR (CDCl 3 , TMS, ppm) ή = 6.87 (s, 3H), 5.87 (d, 7.3, 1H), 4.12
(d, 7.3, 1H), 3.94 (s, 3H), 3.89 (s,
6H), 3.85 (s, 3H) Example 1 A solution of 3.1 g of trifluoroacetic acid in 2 ml of tetrahydrofuran is added to a solution of 1 g of sodium borohydride in 20 ml of tetrahydrofuran at a temperature below 20°C. To this mixture was added a solution of 1.65 g (5.4 mM) of α-hydroxy-1,4,5,8-tetramethoxynaphthalene-2-acetonitrile obtained in Reference Example 2 in 10 ml of tetrahydrofuran at a temperature below 20°C, and then at room temperature. Continue stirring for 4 hours. The reaction mixture was transferred to water, extracted with methylene chloride, and the organic layer was dried, concentrated, and purified by silica gel column chromatography (methanol/chloroform) to obtain α-aminomethyl-1,4,5,8-tetra 500 mg of methoxynaphthalene-2-methanol are obtained as an oil. The structure and physical properties of the obtained compound are shown in Table 1. Example 2 α-aminomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol 310 mg
(1mM) and 300mg of acetone in 5ml of methanol, slowly add 65mg of NaBH 3 CN under ice cooling.
Thereafter, the temperature was gradually returned to room temperature and stirring was continued for 16 hours. The reaction solution was transferred to water, extracted with chloroform,
After drying and concentrating the organic layer, the resulting crude product was purified by silica gel chromatography (chloroform:methanol = 20:1 V/V) to obtain α-(1-methylethyl)aminomethyl-1,4,5 , 8-tetramethoxynaphthalene-2-methanol 272mg
(yield 78%). The structure and physical properties of the compound are shown in Table 1. Examples 3 to 9 Compounds of Examples 3 to 9 shown in Table 1 were obtained in the same manner as in Examples 1 and 2 above. Each of these compounds can also be produced according to the method described in Example 13 below. Example 10 750 mg of α-piperidinomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol was dissolved in 4 ml of pyridine, and 4 ml of acetic anhydride was added.
Stir at ℃ for 3 hours. Transfer to water, extract with ethyl acetate, and wash the organic layer with water. After concentrating the organic layer, the resulting crude product was purified by silica gel chromatography (methanol/chloroform 1/30V/V).
740 mg (88%) of 2-(1-acetoxy-2-piperidinoethyl)-1,4,5,8-tetramethoxynaphthalene are obtained as an oil. Its structure and physical properties are shown in Table 1. Examples 11 and 12 Compounds of Examples 11 and 12 shown in Table 1 below were obtained in the same manner as in Example 10 above. [Table] [Table] [Table] Example 13 2-(1,2-epoxyethyl) obtained in Reference Example 1
-1,4,5,8-tetramethoxynaphthalene 1
g and 4 g of isopropylamine in methanol 60
ml and stirred at room temperature for 6 days. Thereafter, methanol was distilled off, and the obtained oily substance was purified by silica gel column chromatography (chloroform/methanol = 30/1 V/V) to 360 mg (yield: 3
%) of β-(1-methylethyl)amino-1,4,
5,8-tetramethoxynaphthalene-2-ethanol is obtained as an oil. This product could be obtained as a crystal by dissolving it in ethanol, drying it, acidifying it with hydrochloric acid, and adding ether, and its physical properties were consistent with those of the compound obtained in Example 2 above. In addition, in the above silica gel column chromatography, chloroform/methanol = 2
By continuing to develop at 0/1 (V/V ratio), 400
mg (yield 33%) of α-(1-methylethyl)aminomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol is obtained as an oil.
This oil is dissolved in ethanol, dried and
After making it acidic with hydrochloric acid, it can be collected as crystals by adding ether. The structure and physical properties of this compound are shown in Table 2 as Example No. 13. Examples 14 to 21 In the same manner as in Example 13, Examples 14 to 2 shown in Table 2 below were prepared along with each compound shown in Examples 3 to 9.
21 compounds were obtained. Examples 22-24 The same operations as in Example 10 were performed to obtain the compounds of Examples 22-24 shown in Table 2 below. [Table] [Table]

Claims (1)

【特蚱請求の範囲】  䞀般匏 〔匏䞭R1は䜎玚アルコキシ基を瀺す。R2及び
R3は䞀方が氎酞基又は䜎玚アルカノむルオキシ
基を瀺し、他方が基【匏】を瀺す。該基にお いおR4及びR5は同䞀又は盞異な぀お氎玠原子、
䜎玚アルキル基、シクロアルキル基、プニル環
䞊に眮換基ずしお䜎玚アルコキシ基を有するこず
のあるプニル基又はプニル環䞊に眮換基ずし
お䜎玚アルコキシ基を有するこずのあるプニル
䜎玚アルキル基を瀺す。たたR4及びR5は酞玠原
子もしくは窒玠原子を介しもしくは介するこずな
く互に結合しお、隣接する窒玠原子ず共に耇玠環
基を圢成しおもよく、該耇玠環基は曎にプニル
䜎玚アルキル基を眮換基ずしお有しおいおもよ
い。〕 で衚わされる−テトラアルコキシ
ナフタレン誘導䜓及びその塩。
[Claims] 1. General formula [In the formula, R 1 represents a lower alkoxy group. R 2 and
One of R 3 represents a hydroxyl group or a lower alkanoyloxy group, and the other represents a group [Formula]. In this group, R 4 and R 5 are the same or different and are hydrogen atoms,
A lower alkyl group, a cycloalkyl group, a phenyl group that may have a lower alkoxy group as a substituent on the phenyl ring, or a phenyl lower alkyl group that may have a lower alkoxy group as a substituent on the phenyl ring. Furthermore, R 4 and R 5 may be bonded to each other with or without an oxygen atom or a nitrogen atom to form a heterocyclic group together with the adjacent nitrogen atom, and the heterocyclic group may further include a phenyl lower alkyl group. It may be included as a substituent. ] A 1,4,5,8-tetraalkoxynaphthalene derivative and a salt thereof.
JP58209712A 1983-11-07 1983-11-07 1,4,5,8-tetraalkoxynaphthalene derivative Granted JPS60100542A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58209712A JPS60100542A (en) 1983-11-07 1983-11-07 1,4,5,8-tetraalkoxynaphthalene derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58209712A JPS60100542A (en) 1983-11-07 1983-11-07 1,4,5,8-tetraalkoxynaphthalene derivative

Publications (2)

Publication Number Publication Date
JPS60100542A JPS60100542A (en) 1985-06-04
JPH0449536B2 true JPH0449536B2 (en) 1992-08-11

Family

ID=16577393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58209712A Granted JPS60100542A (en) 1983-11-07 1983-11-07 1,4,5,8-tetraalkoxynaphthalene derivative

Country Status (1)

Country Link
JP (1) JPS60100542A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002359A1 (en) * 1985-10-14 1987-04-23 Maggioni-Winthrop S.P.A. Dihydrobenzothiophene and thiochromane aminoalcohols
WO1987002666A2 (en) * 1985-10-31 1987-05-07 Maggioni-Winthrop S.P.A. Bicyclic alkoxy- and alkylthio-substituted aminoalcohols

Also Published As

Publication number Publication date
JPS60100542A (en) 1985-06-04

Similar Documents

Publication Publication Date Title
SU1005655A3 (en) Process for producing 3-aryloxy-3-phenyl-propyl amines or their salts
JPS6012350B2 (en) Method for producing novel arylpiperidine derivatives
LU86435A1 (en) NOVEL MORPHINANE AND MORPHINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPS6330894B2 (en)
JPH0449536B2 (en)
US4705807A (en) Amine derivatives
AU609067B2 (en) Compounds useful as intermediates for the production of substituted 1-pyridyloxy-3-indolyalkylamino-2- propanols
US4927968A (en) Chemical intermediates and process
EP2730562A1 (en) Novel method for synthesising (2E)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid
JPS6236518B2 (en)
JP3492433B2 (en) 3- (Phenylalkylaminoalkyloxy) -5-phenylpyrazole compounds, methods and intermediates for their preparation and cardiovascular agents containing them
US6781003B1 (en) Preparation of pure citalopram
US4020071A (en) Derivatives of 1-phenoxy-3-amino-propan-2-ol
EP1661894A1 (en) Process for production of 4-aminotetrahydropyrans and salts thereof with acids, intermediates for the process, and process for production thereof
EP2719689B1 (en) Novel method for synthesising 3-(2-bromo-4,5-dimethoxyphenyl) propanenitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid
JPH0314296B2 (en)
KR100353661B1 (en) Method for preparing β-nitroenamine and its intermediates
EP0306411A2 (en) Ethanone oximes
JP2801647B2 (en) Method for producing 6-fluorochromone-2-carboxylic acid derivative
KR840001077B1 (en) Process for n4-carbamoylpiperazino propanal derivatives
US6812355B2 (en) Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20060293530A1 (en) Process for the manufacture of citalopram hydrobromide
JP2539261B2 (en) Imidazole derivative
JP4973210B2 (en) New synthesis method
JPH0827109A (en) Method for producing β- (benzyl) indole-3-ethanol